Fuso Pharmaceutical Industries,Ltd.
Notice: Revision of Earnings Guidance and Revision (Increase) of Year-end Dividend Forecast
For the fiscal year ending March 2027, net sales have been raised from 63,200 hundred million yen → 64,800 hundred million yen, operating income from 2,000 million yen → 2,400 million yen, ordinary income from 1,400 million yen → 1,800 million yen, and net income attributable to owners of parent from 1,300 million yen → 1,500 million yen. Concurrently, the year-end dividend forecast is increased from 45 yen → 46 yen. The annual dividend is expected to increase from 90 yen → 91 yen.
Key Figures
- Net Sales: 64,800 hundred million yen
- Operating Income: 2,400 million yen
- Ordinary Income: 1,800 million yen
- Net Income Attributable to Owners of Parent: 1,500 million yen
- Net Income per Share: 175.73 yen
- Year-end Dividend: 46 yen/ shares
- Annual Dividend: 91 yen/ shares
AI要約
Overview of Earnings Guidance Revision
Fuso Pharmaceutical Industries,Ltd. has upwardly revised its full-year earnings guidance for the fiscal year ending March 2027, which was previously announced on May 12, 2026. While first-half sales trends remain firm, price increases in raw materials are expected in the second half. Despite anticipated increases in R&D expenses, the overall outlook is projected to exceed the previous forecast.
Revision of Dividend Forecast and Shareholder Returns
The year-end dividend forecast has been revised from 45 yen per share to 46 yen per share, bringing the annual dividend—including the 45 yen interim dividend—to 91 yen. With a basic policy of strengthening retained earnings and stable dividends and a mid-term management policy aiming for progressive dividends through fiscal 2030, the company will continue to balance investment to reinforce stable supply systems with shareholder returns.
Fuso Pharmaceutical Industries,Ltd.
Company overview · Stock price · Financial data · All IR
